Dare Bioscience DARE 深 沪
等待开盘 11-06 09:30:00 美东时间
0.6309
-0.031
-4.68%
华盛通- 最 高0.6799
- 今 开0.669
- 成交量 14.32万股
- 最 低 0.61
- 昨 收 0.6619
- 总市值 1240.92万
- 52周最高 3.78
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 0.61
- 委 比 -96.08%
- 总股本 1966.91万
- 历史最高 76.44
- 量 比 0.66
- 振 幅 10.56%
- 历史最低 0.61
- 每 手 1
- 风险率 0.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dare Bioscience Inc收涨2.66%，成交额45.57万美元
10月31日，Dare Bioscience Inc（DARE）收涨2.66%，报0.7美元，成交额45.57万美元，市值1376.05万美元。 行情数据 •...
10-31 07:51
Dare Bioscience Inc收跌5.28%，成交额21.1万美元
10月23日，Dare Bioscience Inc（DARE）收跌5.28%，报0.65美元，成交额21.1万美元，市值1281.84万美元。 行情数据 •...
10-23 07:58
Dare Bioscience Inc收跌2.08%，成交额5.59万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:57
Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the issuance of U.S. Patent No. 12,678,439, titled "Lopinavir and Ritonavir for the Treatment of Cervix...
09-28 20:21
Dare Bioscience shares are trading higher after the company reported better-than-expected Q2 financial results.
Dare Bioscience shares are trading higher after the company reported better-than-expected Q2 financial results.
08-14 21:11
Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 55.56 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $187.546 thous...
08-14 04:02
Dare Biosciences Receives Second $1M Tranche Of NIH Funding
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of its
05-26 20:15
电话会总结 ｜ Daré(DARE)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Daré Bioscience业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** - 截至季度末现金及现金等价物约1,850万美元 - 营运资金约50万美元 **费用支出：** - 销售、一般及管理费用（SG&A）：220万美元 - 研发费用（R&D）：70万美元 - 实际研发投资（加回抵消研发费用后）：约420万美元（70万美元 + 350万美元抵消金额） **非稀释性资金：** - 2025年获得：盖茨基金会1,360万美元、ARPA-H奖励450万美元、NIH报销130万美元 - 2026年2月获得：ARPA-H
05-16 12:30
Dare Bioscience Q1 2026 Earnings Call: Complete Transcript
Dare Bioscience (NASDAQ:DARE) released first-quarter financial results and host...
05-15 05:37
Dare Bioscience Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $152.455K Miss $984.667K Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 60 percent increase over losses of $(0.50) per share from the
05-15 04:04
